感染性坏死性胰腺炎的抗菌治疗:微生物学、耐药与药代动力学
本文综述感染性坏死性胰腺炎的抗菌治疗,重点讨论微生物学与药代动力学。感染菌谱以肠道革兰阴性菌为主,长期住院和抗生素暴露可筛选耐药菌;预防性抗生素无效,非碳青霉烯类β-内酰胺类延长输注可能达到足够组织穿透。
要点
- 感染性坏死性胰腺炎死亡率15%-35%,常需侵入性干预和重症监护。
- 预防性抗生素不能预防感染并发症,不推荐常规使用。
- 非碳青霉烯类β-内酰胺类延长输注可能达到足够组织穿透。
核心结论
- 预防性抗生素在预防感染并发症方面临床无效。
- 碳青霉烯类传统上因组织穿透优势受青睐,但药代动力学研究提示非碳青霉烯类β-内酰胺类延长输注也可能达到足够组织穿透。
- 需要以临床终点比较不同抗生素治疗策略的疗效研究。
研究设计与样本
- 综述,总结感染性坏死性胰腺炎抗菌治疗的当前观点,重点为微生物学和药代动力学。
主要发现
- 约20%急性胰腺炎患者进展为坏死性胰腺炎,其中约30%发生感染性胰腺坏死。
- 感染性胰腺坏死微生物谱以肠道菌群易位为主,最常见为大肠埃希菌和克雷伯菌属等革兰阴性菌。
- 肠球菌和念珠菌属也常见,并与不良结局相关;厌氧菌可能因培养局限和抗生素使用而被低估。
- 长期住院和累积抗生素暴露可筛选耐药和难治性病原体。
关键数值与推荐
- 感染性坏死性胰腺炎死亡率15%-35%。
- 约20%急性胰腺炎患者进展为坏死性胰腺炎,其中约30%发生感染性胰腺坏死。
临床怎么用
- 不推荐对急性胰腺炎患者常规预防性使用抗生素以预防感染并发症。
- 治疗感染性胰腺坏死时,可考虑非碳青霉烯类β-内酰胺类(如哌拉西林-他唑巴坦、头孢吡肟)延长输注以达到足够组织穿透。
局限性
- 厌氧菌可能因培养局限和抗生素使用而被低估。
- 缺乏以临床终点比较抗生素治疗策略的疗效研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute pancreatitis is among the most common gastrointestinal disorders requiring hospitalization and can be complicated by serious infections. Approximately 20% of patients progress to necrotizing pancreatitis, of whom ∼30% develop infected pancreatic necrosis, a complication associated with mortality rates of 15%-35% that often necessitates invasive interventions and intensive care treatment. Serious extra-pancreatic infections are also commonly reported in acute pancreatitis patients. This review summarizes current perspectives on antimicrobial therapy for infected pancreatic necrosis, with an emphasis on microbiology and pharmacokinetics. The microbiological spectrum found in infected pancreatic necrosis is predominantly enteric, reflecting translocation of gut flora into necrotic tissue, with Gram-negative bacteria such as Escherichia coli and Klebsiella spp. being most frequently isolated. Enterococci and Candida species are also commonly identified and have been associated with adverse outcome7444444s, while anaerobes are probably underreported due to inherent culture limitations and antibiotic use. Notably, prolonged hospitalization and cumulative antibiotic exposure select for antimicrobial-resistant and difficult-to-treat pathogens. On the basis of robust evidence, prophylactic antibiotics are not clinically effective in preventing infectious complications. Although carbapenems have traditionally been favoured for treatment of infected pancreatic necrosis on the basis of presumed superior tissue penetration, pharmacokinetic studies suggest that non-carbapenem beta-lactams such as piperacillin-tazobactam and cefepime may achieve adequate tissue penetration as well, particularly when administered as extended infusions. Comparative efficacy studies of antibiotic treatment strategies with clinical endpoints are needed.
引用
- Pauw HS, Schwarz R, Beij A, et al. Antimicrobial therapy for infected necrotizing pancreatitis: microbiology, antimicrobial resistance and pharmacokinetics. J Antimicrob Chemother. 2026. PMID: 41808660. doi:10.1093/jac/dkag092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。